Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy
Status:
Terminated
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out how well cetuximab works in treating NSCLC
in patients who have been previously treated with a class of drug called tyrosine kinase
inhibitor (TKI). Cetuximab is a protein that is designed to block a substance in cancer cells
called "epidermal growth factor receptor" or EGFR. EGFR helps cancer cells grow.
Phase:
Phase 2
Details
Lead Sponsor:
Lecia V. Sequist
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Bristol-Myers Squibb Dana-Farber Cancer Institute St. Joseph Hospital Health Center Unity Health Toronto